Colon Pharmaceuticals announced that recently, the controlling shareholder Liu Xinxin released the pledge of 9.167 million shares, accounting for 2.42% of its shares and 0.58% of the company's total share capital; pledged 6.9 million shares, accounting for 1.82% of the company's total share capital, accounting for 0.43% of the company's total share capital, locking in shares for executives to use in their personal capital needs. As of the disclosure date of the announcement, Liu Xinxin and his co-actors have pledged a total of 89.02 million shares, accounting for 22.96% of their shares and 5.60% of the company's total share capital. This pledge will not result in a change in the actual controller and will not adversely affect the company.

Colon Pharmaceuticals announced that recently, the controlling shareholder Liu Xinxin released the pledge of 9.167 million shares, accounting for 2.42% of its shares and 0.58% of the company's total share capital; pledged 6.9 million shares, accounting for 1.82% of the company's total share capital, accounting for 0.43% of the company's total share capital, locking in shares for executives to use in their personal capital needs. As of the disclosure date of the announcement, Liu Xinxin and his co-actors have pledged a total of 89.02 million shares, accounting for 22.96% of their shares and 5.60% of the company's total share capital. This pledge will not result in a change in the actual controller and will not adversely affect the company.